Email this article Optimization of sequential targeted therapy
- Authors: Alekseev B.Y.1, Kalpinskiy A.S.1, Nyushko K.M.1, Taraki I.A.1, Kaprin A.D.1
-
Affiliations:
- Moscow Research Oncological Institute named after P.A. Herzen – affiliated by the Federal State Budgetary Institution “National Medical Research Radiological Center”, Russian Ministry of Health
- Issue: Vol 12, No 3 (2016)
- Pages: 22-29
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. RENAL CANCER
- Published: 30.09.2016
- URL: https://oncourology.abvpress.ru/oncur/article/view/604
- DOI: https://doi.org/10.17650/1726-9776-2016-12-3-22-29
- ID: 604
Cite item
Abstract
Renal cell carcinoma (RCC) takes one of the leading places in the world incidence among malignant tumors of the genitourinary system. Metastatic renal cell cancer (mRCC) is detected in about 25–30 % of primary patients. 10 targeted immuno-oncology drugs for the treatment of mRCC were registered and approved for use from 2005 till the present time. Rapid growth of therapeutic options of mRCC treatment has created a problem for practicing oncologists and urologists as well as necessity to understand the principles and consistent optimization of targeted therapy to maximize the effectiveness of each treatment line. The article discusses issues of the correct choice of first-line targeted drugs, optimal dosing of sunitinib and aksitinib, alternative modes and alternating use of sunitinib, as well as the influence of objective response and hypertension, which developed on the background of the targeted therapy on the effectiveness of treatment.
About the authors
B. Ya. Alekseev
Moscow Research Oncological Institute named after P.A. Herzen – affiliated by the Federal State Budgetary Institution “National Medical Research Radiological Center”, Russian Ministry of Health3 2nd Botkinskiy Proezd, Moscow, 125284 Russian Federation
A. S. Kalpinskiy
Moscow Research Oncological Institute named after P.A. Herzen – affiliated by the Federal State Budgetary Institution “National Medical Research Radiological Center”, Russian Ministry of Health3 2nd Botkinskiy Proezd, Moscow, 125284 Russian Federation
K. M. Nyushko
Moscow Research Oncological Institute named after P.A. Herzen – affiliated by the Federal State Budgetary Institution “National Medical Research Radiological Center”, Russian Ministry of Health
Author for correspondence.
Email: kirandja@ya.ru
3 2nd Botkinskiy Proezd, Moscow, 125284 Russian Federation
I. A. Taraki
Moscow Research Oncological Institute named after P.A. Herzen – affiliated by the Federal State Budgetary Institution “National Medical Research Radiological Center”, Russian Ministry of Health3 2nd Botkinskiy Proezd, Moscow, 125284 Russian Federation
A. D. Kaprin
Moscow Research Oncological Institute named after P.A. Herzen – affiliated by the Federal State Budgetary Institution “National Medical Research Radiological Center”, Russian Ministry of Health3 2nd Botkinskiy Proezd, Moscow, 125284 Russian Federation
References
Supplementary files
